Retrovirology



Poster presentation

Open Access

HIV activates indoleamine 2,3-dioxygenease: inhibition of T cell proliferation by tryptophan starvation

A Boasso*1, AW Hardy¹, JP Herbeuval¹, SA Anderson², MJ Dolan², JD Lifson³, D Fuchs⁴ and GM Shearer¹

Address: ¹Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA, ²Henry M. Jackson Foundation and Infectious Diseases Service Wilford Hall Medical Center, Lackland Air Force Base, Texas, USA, ³Division of Biological Chemistry, Innsbruck Medical University, Innsbruck, Austria and ⁴AIDS Vaccine Program, SAIC, National Cancer Institute, Frederick, Maryland, USA

* Corresponding author

from 2006 International Meeting of The Institute of Human Virology Baltimore, USA. 17–21 November, 2006

Published: 21 December 2006

Retrovirology 2006, 3(Suppl I):PII doi:10.1186/1742-4690-3-SI-PII

© 2006 Boasso et al; licensee BioMed Central Ltd.

T cell immune responses of HIV+ patients are functionally impaired prior to CD4+ T cell depletion. Tryptophan (trp) degradation by indoleamine-2, 3-dyoxigenase (IDO) is an immunosuppressive system that may be important in HIV/AIDS. We show here that IDO is increased in PBMC from HIV+ patients compared to controls. Culture with the IDO-inhibitor 1-methyl tryptophan (1 mT) increased proliferation of PBMC from HIV+ patients in response to PHA or anti-CD3/CD28. Exposure of PBMC from HIVuninfected donors to infectious or noninfectious HIV increased IDO in plasmacytoid dendritic cells (pDC). Supernatants from HIV-exposed PBMC inhibited CD4+ T cell responses to PHA or anti-CD3/CD28, and this effect was reversed by 1 mT. CD8+ T cell proliferation in response to anti-CD3/CD28, but not to PHA, was also inhibited. Analysis of cyclin mRNA expression showed that CD4+ T cell were arrested in G1, whereas CD8+ T cell were blocked in G0. HIV-induced IDO inhibited expression of CD28 mRNA in CD8+ T cells. Thus HIV directly induces IDO expression in pDC, resulting in unresponsiveness of CD4+ T cells by inhibiting progression to the S phase of the cell cycle, and blocking of CD8+ T cell costimulation through downregulation of CD28.